Creation of nano eye-drops and effective drug delivery to the interior of the eye
Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-si...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2017-03, Vol.7 (1), p.44229-44229, Article 44229 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 44229 |
|---|---|
| container_issue | 1 |
| container_start_page | 44229 |
| container_title | Scientific reports |
| container_volume | 7 |
| creator | Ikuta, Yoshikazu Aoyagi, Shigenobu Tanaka, Yuji Sato, Kota Inada, Satoshi Koseki, Yoshitaka Onodera, Tsunenobu Oikawa, Hidetoshi Kasai, Hitoshi |
| description | Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment. |
| doi_str_mv | 10.1038/srep44229 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5349510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1903383488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-53ff0d9e32c341a4fec772c335627a298d0b7e3bf819ef372dc6969e78e9c0bf3</originalsourceid><addsrcrecordid>eNplkU1LAzEQhoMottQe_AMS8KLCajYf3eQiSPELCiLoOaS7k3bLNqnJrtB_b0q1VM0lM8wz70zyInSak-ucMHkTA6w4p1QdoD4lXGSUUXq4F_fQMMYFSUdQxXN1jHpUUkW4HPXR6ziAaWvvsLfYGecxrCGrgl9FbFyFwVoo2_oTcBW6Ga6gSXFY49bjdg64di2E2odN9yZPzSfoyJomwvD7HqD3h_u38VM2eXl8Ht9NslIQ3maCWUsqBYyWjOeGpzFFkWImRrQwVMmKTAtgUytzBZYVtCpHaqSgkKBKMrVsgG63uqtuuoSqBNcG0-hVqJcmrLU3tf5dcfVcz_ynFowrkb5ugC6-BYL_6CC2elnHEprGOPBd1LksCkElEyyh53_Qhe-CS8_TuSKMScalTNTlliqDj8kWu1smJ3rjld55ldiz_e135I8zCbjaAjGV3AzC3sh_al-J653h</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1903383488</pqid></control><display><type>article</type><title>Creation of nano eye-drops and effective drug delivery to the interior of the eye</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Ikuta, Yoshikazu ; Aoyagi, Shigenobu ; Tanaka, Yuji ; Sato, Kota ; Inada, Satoshi ; Koseki, Yoshitaka ; Onodera, Tsunenobu ; Oikawa, Hidetoshi ; Kasai, Hitoshi</creator><creatorcontrib>Ikuta, Yoshikazu ; Aoyagi, Shigenobu ; Tanaka, Yuji ; Sato, Kota ; Inada, Satoshi ; Koseki, Yoshitaka ; Onodera, Tsunenobu ; Oikawa, Hidetoshi ; Kasai, Hitoshi</creatorcontrib><description>Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/srep44229</identifier><identifier>PMID: 28290486</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>140/131 ; 639/638/298/54/152 ; 639/638/298/54/990 ; Cholesterol ; Cornea ; Drug delivery ; Drug delivery systems ; Drug efficacy ; Epithelium ; Eye ; Fabrication ; Glaucoma ; Humanities and Social Sciences ; multidisciplinary ; Nanocrystals ; Nanoparticles ; R&D ; Research & development ; Science ; Side effects</subject><ispartof>Scientific reports, 2017-03, Vol.7 (1), p.44229-44229, Article 44229</ispartof><rights>The Author(s) 2017</rights><rights>Copyright Nature Publishing Group Mar 2017</rights><rights>Copyright © 2017, The Author(s) 2017 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-53ff0d9e32c341a4fec772c335627a298d0b7e3bf819ef372dc6969e78e9c0bf3</citedby><cites>FETCH-LOGICAL-c504t-53ff0d9e32c341a4fec772c335627a298d0b7e3bf819ef372dc6969e78e9c0bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349510/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349510/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,41099,42168,51555,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28290486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ikuta, Yoshikazu</creatorcontrib><creatorcontrib>Aoyagi, Shigenobu</creatorcontrib><creatorcontrib>Tanaka, Yuji</creatorcontrib><creatorcontrib>Sato, Kota</creatorcontrib><creatorcontrib>Inada, Satoshi</creatorcontrib><creatorcontrib>Koseki, Yoshitaka</creatorcontrib><creatorcontrib>Onodera, Tsunenobu</creatorcontrib><creatorcontrib>Oikawa, Hidetoshi</creatorcontrib><creatorcontrib>Kasai, Hitoshi</creatorcontrib><title>Creation of nano eye-drops and effective drug delivery to the interior of the eye</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment.</description><subject>140/131</subject><subject>639/638/298/54/152</subject><subject>639/638/298/54/990</subject><subject>Cholesterol</subject><subject>Cornea</subject><subject>Drug delivery</subject><subject>Drug delivery systems</subject><subject>Drug efficacy</subject><subject>Epithelium</subject><subject>Eye</subject><subject>Fabrication</subject><subject>Glaucoma</subject><subject>Humanities and Social Sciences</subject><subject>multidisciplinary</subject><subject>Nanocrystals</subject><subject>Nanoparticles</subject><subject>R&D</subject><subject>Research & development</subject><subject>Science</subject><subject>Side effects</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNplkU1LAzEQhoMottQe_AMS8KLCajYf3eQiSPELCiLoOaS7k3bLNqnJrtB_b0q1VM0lM8wz70zyInSak-ucMHkTA6w4p1QdoD4lXGSUUXq4F_fQMMYFSUdQxXN1jHpUUkW4HPXR6ziAaWvvsLfYGecxrCGrgl9FbFyFwVoo2_oTcBW6Ga6gSXFY49bjdg64di2E2odN9yZPzSfoyJomwvD7HqD3h_u38VM2eXl8Ht9NslIQ3maCWUsqBYyWjOeGpzFFkWImRrQwVMmKTAtgUytzBZYVtCpHaqSgkKBKMrVsgG63uqtuuoSqBNcG0-hVqJcmrLU3tf5dcfVcz_ynFowrkb5ugC6-BYL_6CC2elnHEprGOPBd1LksCkElEyyh53_Qhe-CS8_TuSKMScalTNTlliqDj8kWu1smJ3rjld55ldiz_e135I8zCbjaAjGV3AzC3sh_al-J653h</recordid><startdate>20170314</startdate><enddate>20170314</enddate><creator>Ikuta, Yoshikazu</creator><creator>Aoyagi, Shigenobu</creator><creator>Tanaka, Yuji</creator><creator>Sato, Kota</creator><creator>Inada, Satoshi</creator><creator>Koseki, Yoshitaka</creator><creator>Onodera, Tsunenobu</creator><creator>Oikawa, Hidetoshi</creator><creator>Kasai, Hitoshi</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170314</creationdate><title>Creation of nano eye-drops and effective drug delivery to the interior of the eye</title><author>Ikuta, Yoshikazu ; Aoyagi, Shigenobu ; Tanaka, Yuji ; Sato, Kota ; Inada, Satoshi ; Koseki, Yoshitaka ; Onodera, Tsunenobu ; Oikawa, Hidetoshi ; Kasai, Hitoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-53ff0d9e32c341a4fec772c335627a298d0b7e3bf819ef372dc6969e78e9c0bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>140/131</topic><topic>639/638/298/54/152</topic><topic>639/638/298/54/990</topic><topic>Cholesterol</topic><topic>Cornea</topic><topic>Drug delivery</topic><topic>Drug delivery systems</topic><topic>Drug efficacy</topic><topic>Epithelium</topic><topic>Eye</topic><topic>Fabrication</topic><topic>Glaucoma</topic><topic>Humanities and Social Sciences</topic><topic>multidisciplinary</topic><topic>Nanocrystals</topic><topic>Nanoparticles</topic><topic>R&D</topic><topic>Research & development</topic><topic>Science</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ikuta, Yoshikazu</creatorcontrib><creatorcontrib>Aoyagi, Shigenobu</creatorcontrib><creatorcontrib>Tanaka, Yuji</creatorcontrib><creatorcontrib>Sato, Kota</creatorcontrib><creatorcontrib>Inada, Satoshi</creatorcontrib><creatorcontrib>Koseki, Yoshitaka</creatorcontrib><creatorcontrib>Onodera, Tsunenobu</creatorcontrib><creatorcontrib>Oikawa, Hidetoshi</creatorcontrib><creatorcontrib>Kasai, Hitoshi</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ikuta, Yoshikazu</au><au>Aoyagi, Shigenobu</au><au>Tanaka, Yuji</au><au>Sato, Kota</au><au>Inada, Satoshi</au><au>Koseki, Yoshitaka</au><au>Onodera, Tsunenobu</au><au>Oikawa, Hidetoshi</au><au>Kasai, Hitoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Creation of nano eye-drops and effective drug delivery to the interior of the eye</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2017-03-14</date><risdate>2017</risdate><volume>7</volume><issue>1</issue><spage>44229</spage><epage>44229</epage><pages>44229-44229</pages><artnum>44229</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>28290486</pmid><doi>10.1038/srep44229</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2017-03, Vol.7 (1), p.44229-44229, Article 44229 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5349510 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature OA Free Journals; Nature Free; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | 140/131 639/638/298/54/152 639/638/298/54/990 Cholesterol Cornea Drug delivery Drug delivery systems Drug efficacy Epithelium Eye Fabrication Glaucoma Humanities and Social Sciences multidisciplinary Nanocrystals Nanoparticles R&D Research & development Science Side effects |
| title | Creation of nano eye-drops and effective drug delivery to the interior of the eye |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A53%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Creation%20of%20nano%20eye-drops%20and%20effective%20drug%20delivery%20to%20the%20interior%20of%20the%20eye&rft.jtitle=Scientific%20reports&rft.au=Ikuta,%20Yoshikazu&rft.date=2017-03-14&rft.volume=7&rft.issue=1&rft.spage=44229&rft.epage=44229&rft.pages=44229-44229&rft.artnum=44229&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/srep44229&rft_dat=%3Cproquest_pubme%3E1903383488%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1903383488&rft_id=info:pmid/28290486&rfr_iscdi=true |